MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-14-2026
QIAGEN N.V. General and Administrative Expenses 2011-2026 | QGEN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses QIAGEN N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 128 M | 112 M | 112 M | 141 M | 200 M | 129 M | 104 M | 127 M | 199 M | 152 M | 186 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 104 M | 145 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
314 M | $ 9.2 | 2.17 % | $ 613 M |  USA |
|
Biodesix
BDSX
|
80.5 M | $ 15.36 | 4.56 % | $ 1.99 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.14 | 0.47 % | $ 4.92 M | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 16.25 | -0.49 % | $ 491 M | USA |
 |
Guardant Health
GH
|
211 M | $ 83.44 | -1.79 % | $ 10.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 102.22 | 1.86 % | $ 8.43 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 572.04 | -1.12 % | $ 46 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 74.38 | -1.79 % | $ 5.02 B | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M |  Israel |
 |
Medpace Holdings
MEDP
|
198 M | $ 463.54 | 1.45 % | $ 13.4 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.67 | 0.11 % | $ 432 M | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.35 | -0.91 % | $ 388 M | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.39 | -0.36 % | $ 417 M | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
14.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Precipio
PRPO
|
9.45 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
46.2 M | $ 7.71 | 1.31 % | $ 457 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
RadNet
RDNT
|
1.82 M | $ 59.66 | -3.37 % | $ 4.49 B | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 159.73 | 1.09 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 165.68 | -0.77 % | $ 28.5 B | USA |
 |
Sotera Health Company
SHC
|
253 M | $ 13.83 | -0.36 % | $ 3.93 B | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | $ 31.01 | -2.24 % | $ 1.58 B | USA |
 |
Neuronetics
STIM
|
31.5 M | $ 1.45 | -9.69 % | $ 95.6 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.23 | -15.75 % | $ 6.7 M | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 263.12 | 1.94 % | $ 26 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
9.49 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 125.57 | 1.44 % | $ 20 B | USA |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 46.42 | 4.31 % | $ 2.78 B | USA |
 |
Celcuity
CELC
|
9.06 M | $ 101.62 | -4.81 % | $ 4.01 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 267.18 | 1.04 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
7.06 M | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 7.91 | -2.41 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
589 M | $ 194.73 | -2.68 % | $ 19.2 B | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 6.62 | - | $ 276 M | USA |